ICS cohorts (n=26,834) ICS/LABA cohorts (n=20,814)
Characteristic Switch to QD
 (n=941)
Remain on BD
 (n=25,893)
p value* Switch to QD
 (n=505)
Remain on BD
 (n=20,309)
p value*
Year of index prescription, mean (SD) 2000.8 (4.7) 1999.6 (4.3) <0.001 2003.4 (3.6) 2003.2 (3.3) 0.002
ICS drug prescribed at the index date            
Beclomethasone 353 (37.5) 18,249 (70.5) <0.001 48 (9.5) 5474 (27.0) <0.001
Fluticasone 130 (13.8) 2790 (10.8)   184 (36.4) 9309 (45.8)  
Mometasone 53 (5.6) 10 (0.0)   20 (4.0) 19 (0.1)  
Budesonide 272 (28.9) 4841 (18.7)   126 (25.0) 5495 (27.1)  
Ciclesonide 133 (14.1) 3 (0.0)   127 (25.1) 12 (0.1)  
ICS dose† prescribed at the index date, n (%)            
≤ 200 µg/day 748 (79.5) 13,758 (53.1) <0.001 331 (65.5) 5091 (25.1) <0.001
201-400 µg/day 145 (15.4) 10,100 (39.0)   75 (14.9) 8827 (43.5)  
>400 µg/day 48 (5.1) 2035 (7.9)   99 (19.6) 6391 (31.5)  
Percentage step-down in ICS dose, n (%)            
50% 493 (52.4) 20,093 (77.6) <0.001 237 (46.9) 12,079 (59.5) <0.001
>50% 448 (47.6) 5800 (22.4)   268 (53.1) 8230 (40.5)  

2 test; †The ICS dose is the beclomethasone dipropionate-equivalent.
BD: Twice Daily; ICS: Inhaled Corticosteroid; LABA: Long-Acting β-Agonist; QD: Once Daily
Table 2: Inhaled corticosteroid drug and dose prescribed on the index date when patients were stepped down by ≥ 50% in ICS dose.
Goto home»